Aldeyra Therapeutics to Host 2020 Research & Development Day

Live Webcast Scheduled to Begin at Noon ET Monday, February 24, 2020

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that it will host a Research & Development Day on Monday, February 24, 2020, to provide an update on current late-stage clinical development programs.

The event will include presentations from members of the Aldeyra executive team and Paul Karpecki, O.D., FAAO. Dr. Karpecki is Clinical Director, Corneal Services and Advanced Ocular Surface Disease at Kentucky Eye Institute and a clinician for Gaddie Eye Centers. He also is an Associate Professor at the Kentucky College of Optometry and the Medical Director for Keplr Vision and the Dry Eye Institutes of Kentucky and Indiana.

The presentations will focus on the company’s development plans and market opportunities for its novel product candidates in dry eye disease, allergic conjunctivitis, and proliferative vitreoretinopathy.

The presentations are scheduled to begin at Noon (ET) Monday, February 24, 2020, in New York, NY.

A live audio webcast of the presentation and a slide deck will be available via the company's Investor Relations website at https://ir.aldeyra.com/. Following the live webcast, an archived version will be available on the website for 90 days.

About Aldeyra Therapeutics
Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead investigational drug product candidates are potential first-in-class treatments in development for dry eye disease, allergic conjunctivitis, proliferative vitreoretinopathy, and Sjögren-Larsson Syndrome. The company is also developing other product candidates for retinal and systemic inflammatory diseases.